Parkinson's Disease Clinical Trial
— PARKEOOfficial title:
Sub-thalamic Nucleus Stimulation in Parkinson Disease: Comparison of a Two-steps Electrophysiological Approach Under Local and General Anesthesia and a One-step Approach Under General Anesthesia
Verified date | August 2017 |
Source | University Hospital, Bordeaux |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Deep brain stimulation (DBS) is an established procedure for the symptomatic treatment of
Parkinson's disease. This procedure performed in two steps using electrophysiology. This
study is a prospective, randomized and monocentric study to compare two DBS procedures with
or without electrophysiology.
A better control of targeting and trajectory is necessary before not using electrophysiology,
which is the reference procedure. A new definition of sub thalamic nuclei with new MRI
stereotactic landmarks, the use of surgical robot (Neuromata Renishaw) and the use of
operative imaging (O-arm) could allow the implantation of electrode in sub-thalamic nuclei
without the need of electrophysiology.
Two groups of patients will be followed: a first group of patients with a procedure under
general anesthesia alone without electrophysiological stimulation and a second smaller group
of patients with a first step of electrode implantation under awake surgery with
electrophysiological stimulation followed by a second step under general anesthesia for the
implantation of stimulator.
Clinical results will be assessed at 6 months after implantation.
Status | Completed |
Enrollment | 30 |
Est. completion date | September 9, 2016 |
Est. primary completion date | September 9, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Age : between 18 and 70 years old - Parkinson disease in fluctuation state despite the use of an optimal medical treatment - Dopa sensibility higher than 50% with the L-DOPA test - Normal MRI - Mattis Scale > 130 - Surgical indication approved by a multidisciplinary team - Patient covered by a social insurance - Informed consent signed by patient and investigator Exclusion Criteria: - Patients with surgical or anesthetic contraindications - Cerebral atrophy or signal abnormalities on MRI - Severe Depressive State : The Beck Scale score > 15 - Women of childbearing potential without efficient contraceptive mean - Need of long-term antithrombotic treatment |
Country | Name | City | State |
---|---|---|---|
France | University Hospital | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011 Feb;68(2):165. doi: 10.1001/archneurol.2010.260. Epub 2010 Oct 11. Review. — View Citation
Cuny E, Guehl D, Burbaud P, Gross C, Dousset V, Rougier A. Lack of agreement between direct magnetic resonance imaging and statistical determination of a subthalamic target: the role of electrophysiological guidance. J Neurosurg. 2002 Sep;97(3):591-7. — View Citation
Ferrara J, Diamond A, Hunter C, Davidson A, Almaguer M, Jankovic J. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 Mar;81(3):315-9. doi: 10.1136/jnnp.2009.184127. Epub 2009 Sep 1. — View Citation
Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, Jankovic J. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr;106(4):621-5. — View Citation
Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006 Jun;21 Suppl 14:S290-304. Review. — View Citation
Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998 Oct 15;339(16):1105-11. — View Citation
Maltête D, Navarro S, Welter ML, Roche S, Bonnet AM, Houeto JL, Mesnage V, Pidoux B, Dormont D, Cornu P, Agid Y. Subthalamic stimulation in Parkinson disease: with or without anesthesia? Arch Neurol. 2004 Mar;61(3):390-2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the ratio of preoperative and postoperative UPDRS 3 score | The primary outcome is defined after six months of sub-thalamic nucleus deep brain stimulation with the ratio of preoperative and postoperative UPDRS 3 score. The ratio is : (post operative UPDRS 3 OFF medicine and OFF stimulation- post operative UPDRS 3 OFF medicine ON stimulation)/(post operative UPDRS 3 OFF medicine OFF stimulation) | 6 month | |
Secondary | Stimulation efficacy | Efficacy with the ratio : (Preoperative UPDRS 3 OFF medicine - post operative UPDRS 3 OFF medicine ON stimulation)/( preoperative UPDRS 3 OFF medicine ) | 6 month | |
Secondary | The variance of improvement mean for the "high precision" technique | The variance of improvement mean for the "high precision" technique | 6 month | |
Secondary | Percentage of patients with an improvement of UPDRS III score | Percentage of patients with an improvement of UPDRS III score of 35%, 50% et 65% | 6 month | |
Secondary | The Calculated preoperative and post operative (6 months) equivalent dose of L-DOPA and the decrease of between preoperative and post operative period (6 months). | The Calculated preoperative and post operative (6 months) equivalent dose of L-DOPA and the decrease of between preoperative and post operative period (6 months). | 6 month | |
Secondary | Percentage of patients with failure of the new surgical technique defined with an improvement of less than 35 % with the UPDRS 3 score and an electrode located more than 4 mm from the target | Percentage of patients with failure of the new surgical technique defined with an improvement of less than 35 % with the UPDRS 3 score and an electrode located more than 4 mm from the target | 6 month | |
Secondary | Quality of Life | Quality of Life scale : PDQ-39 | 6 month | |
Secondary | Non motor items of UPDRS score in the high precision technique under general anesthesia alone | Non motor items of UPDRS score in the high precision technique under general anesthesia alone | 6 month | |
Secondary | Adverse effects and complications | Adverse effects and complications : infection, haemorrhages, paresthesia, hypophonia and dyskinesia | 6 month | |
Secondary | Percentage of improvement in patients with the reference technique | Percentage of improvement in patients with the reference technique (electrophysiological approach in awake surgery) | 6 month | |
Secondary | Compare the technical feasibility for both surgeries based on the number of electrodes implanted in the target | Compare the technical feasibility for both surgeries based on the number of electrodes implanted in the target | after surgery | |
Secondary | Operative and postoperative surgical adverse effects. | Operative and postoperative surgical adverse effects. | 6 month | |
Secondary | Evaluate the influence of two operative procedures on the onset and maintenance of post-operative PTSD | Evaluate the influence of two operative procedures on the onset and maintenance of post-operative PTSD | 6 month | |
Secondary | Evaluate the influence of two operative procedures on the level of preoperative anxiety and the time course of this anxiety | Evaluate the influence of two operative procedures on the level of preoperative anxiety and the time course of this anxiety | 1, 3 and 6 month | |
Secondary | Differentiate thymic and cognitive factors potentially predictors of the occurrence of post-surgical PTSD | Differentiate thymic and cognitive factors potentially predictors of the occurrence of post-surgical PTSD | 6 month | |
Secondary | Evaluate the long-term effects of the two operating procedures on thymic and cognitive state | Evaluate the long-term effects of the two operating procedures on thymic and cognitive state | 6 month | |
Secondary | Evaluate the dose of irradiation received by patients during surgery in both procedures | During surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |